A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Phase 3 Completed NCT03895203

Condition	Psoriatic Arthritis
Phase	Phase 3
Sponsor	UCB Biopharma SRL
Status	Completed
Enrollment	852 participants
Interventions	Bimekizumab, Adalimumab
Start date	Apr 3, 2019
Completion date	Aug 17, 2021
Results posted	Oct 23, 2024

Summary

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16

Week 16 · percentage of participants

Placebo	10.0 percentage of participants
BKZ 160 mg Q4W	43.9 percentage of participants
ADA 40 mg Q2W	45.7 percentage of participants

p-value	<0.001
Odds Ratio (OR)	7.082 (95% CI 4.583–10.943)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский